thrombi blood clots.
ASPIRIN WAS THE ONLY ANTIPLATELET AGENT available from the 1970s to the 1980s. Today we now have more than five agents available. These cardioactive drugs are useful in the prevention of thrombi in coronary arteries and those arteries that supply the brain, but they are much less effective in preventing thrombi that occur in
veins. Antiplatelet agents are used in virtually all patients with coronary artery disease to manage the acute and chronic phases of the disease as well as its complications.

Страницы: 1 | 2

• I. MECHANISM OF ACTION
  Coronary thrombosis is known to be the major cause of coronary artery occlusion resulting in fatal or nonfatal acute myocardial infarction. Antiplatelet agents are named this because they inhibit platelet aggregation, which plays a major role in coronary thrombosis, myo-cardial infarction, and cardiac death.
• II. INDICATIONS
  Antiplatelet agents are of proven value in the manage¬ment of non-ST segment elevation myocardial infarction; stable and unstable angina; post coronary artery bypass graft (CABG), coronary artery stents, cerebral transient ischemic attacks (TIAs); and lone atrial fibrillation in individuals younger than 65.
• III. AVAILABLE ANTIPLATELET AGENTS
  Currently used antiplatelet agents include aspirin, clo-pidogrel (ticlopidine still has a role, see Section III.B), dipyridamole plus aspirin, and platelet glycoprotein IIb/IIIa receptor blockers.
• BIBLIOGRAPHY
  Cannon, C. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes. Insights from the TACTICS TIMI-18 Trial. J. Am. Coll. Cardiol., 41:43–48S, 2003.

free dust game